"The promotion and development of medicinal products for the treatment of rare diseases require our particular attention, as health is our most valuable possession," said Ursula Schleicher, former Vice-President of the European Parliament. According to estimates, around 25 million people in Europe are suffering from 5,000 to 8,000 orphan diseases. Many of them are still waiting for medicines that will allow them to at least be able to lead a pain-free life, if not always a normal life. From a purely business-management ...
Read More
"The promotion and development of medicinal products for the treatment of rare diseases require our particular attention, as health is our most valuable possession," said Ursula Schleicher, former Vice-President of the European Parliament. According to estimates, around 25 million people in Europe are suffering from 5,000 to 8,000 orphan diseases. Many of them are still waiting for medicines that will allow them to at least be able to lead a pain-free life, if not always a normal life. From a purely business-management viewpoint, the development of drugs for rare diseases is not always economical for the pharmaceutical industry. Nor can sufferers raise the funds themselves for research into the drugs that for them are vitally necessary. It is, therefore, a question of moral values and national priorities as to what extent society is prepared to help those affected. In 1999 the European Union adopted the Orphan Medicinal Products Regulation. This offers the biopharmaceutical and pharmaceutical industry incentives to develop orphan drugs. This book presents the European Orphan Medicinal Products Regulation and compares it with the rules of other countries. It also discusses the possibilities of creating further incentives.
Read Less
Add this copy of Orphan Drugs a Challenge for the Pharmaceutical to cart. $30.13, new condition, Sold by Books2anywhere rated 5.0 out of 5 stars, ships from Fairford, GLOUCESTERSHIRE, UNITED KINGDOM, published 2005 by Health Economics Research Zentrum (Herz).
Publisher:
Health Economics Research Zentrum (Herz)
Published:
6/17/2005 12: 00: 00 AM
Language:
German
Alibris ID:
18173153269
Shipping Options:
Standard Shipping: $4.70
Choose your shipping method in Checkout. Costs may vary based on destination.
Seller's Description:
PLEASE NOTE, WE DO NOT SHIP TO DENMARK. New Book. Shipped from UK in 4 to 14 days. Established seller since 2000. Please note we cannot offer an expedited shipping service from the UK.
Add this copy of Orphan Drugs: A Challenge for the Pharmaceutical to cart. $30.34, new condition, Sold by Ingram Customer Returns Center rated 5.0 out of 5 stars, ships from NV, USA, published 2005 by Health Economics Research Zentrum (Herz).
Add this copy of Orphan Drugs a Challenge for the Pharmaceutical to cart. $31.56, new condition, Sold by Paperbackshop International rated 2.0 out of 5 stars, ships from Fairford, GLOS, UNITED KINGDOM, published 2005 by Health Economics Research Zentrum (Herz).
Publisher:
Health Economics Research Zentrum (Herz)
Published:
6/17/2005 12: 00: 00 AM
Language:
German
Alibris ID:
18138883418
Shipping Options:
Standard Shipping: $4.70
Choose your shipping method in Checkout. Costs may vary based on destination.
Seller's Description:
PLEASE NOTE, WE DO NOT SHIP TO DENMARK. New Book. Shipped from UK in 4 to 14 days. Established seller since 2000. Please note we cannot offer an expedited shipping service from the UK.
Add this copy of Orphan Drugs: a Challenge for the Pharmaceutical to cart. $56.02, good condition, Sold by Bonita rated 4.0 out of 5 stars, ships from Newport Coast, CA, UNITED STATES, published 2005 by Health Economics Research Zent.
